Hot Products
0102030405
Benfotiamine: Premium Lipid-Soluble Vitamin B1 from China Suppliers and Factory - Highest Bioavailability
C19H23N4O6PS
Description
As a synthetic derivative of vitamin B1 (thiamine), benfotiamine significantly surpasses ordinary vitamin B1 in bioavailability, targeting and clinical efficacy through structural optimization and pharmacokinetic improvement. The specific advantages are as follows:
1
Structural Innovation: Lipid-Soluble Modification Breaks Through Absorption Limitations
Ordinary vitamin B1 (thiamine) is a water-soluble molecule that relies on intestinal sodium-dependent carriers (ThTr1/2) for active transport. It has a low absorption rate (<5%) and is easily saturated — high doses are easily excreted.
Benfotiamine is converted into a lipid-soluble prodrug by introducing benzoyl and phosphate groups (structural formula C19H23N4O6PS), which can bypass carrier restrictions and directly penetrate intestinal mucosal cells through passive diffusion.
>80%
Absorption Efficiency
of Benfotiamine
of Benfotiamine
3–5×
Bioavailability vs.
Ordinary B1
Ordinary B1
<5%
Absorption Rate
of Ordinary B1
of Ordinary B1
2
Pharmacokinetic Advantages: Long-Term Effect and Tissue Targeting
Ordinary B1 has a short half-life in the blood (about 3.5 hours) and is easily cleared quickly by the kidneys. Benfotiamine is hydrolyzed into active thiamine by phosphatase in the body and further converted into thiamine pyrophosphate (TPP). Its lipid solubility makes it easier to accumulate in the phospholipid layer of the cell membrane, prolonging the duration of action.
It can effectively act on the central and peripheral nervous systems, with penetration through the blood-brain barrier and nerve sheath 8–10 times that of ordinary B1. Neurochem Res, 2016
>6 hrs
Half-life of
Benfotiamine
Benfotiamine
3.5 hrs
Half-life of
Ordinary B1
Ordinary B1
8–10×
Blood-Brain Barrier
Penetration vs. B1
Penetration vs. B1
3
Metabolic Regulation: Multi-Target Inhibition of Glucotoxic Damage
In a hyperglycemic environment, ordinary B1 is difficult to effectively inhibit abnormal glucose metabolism pathways due to poor tissue permeability. Benfotiamine shows unique advantages through the following mechanisms:
- ◆ Blocking AGEs Generation: Inhibiting hexosamine and polyol pathways, reducing the accumulation of advanced glycation end products (AGEs), and alleviating axonal damage in diabetic neuropathy. Diabetes, 2010
- ◆ Anti-Inflammatory & Antioxidant: Downregulating the activity of NF-κB and TXNIP/NLRP3 inflammasomes, reducing inflammatory factors such as IL-6 and TNF-α, while enhancing glutathione reductase activity and alleviating oxidative stress.
- ◆ Mitochondrial Protection: Restoring the function of pyruvate dehydrogenase complex (PDH), improving the efficiency of the tricarboxylic acid cycle, and reducing lactic acid accumulation.
4
Clinical Efficacy: High-Dose Tolerance and Deep Repair
Ordinary B1 requires extremely high doses (≥300 mg/day) to treat diabetic neuropathy, but its efficacy is limited due to its absorption rate. Benfotiamine can stably increase tissue TPP concentration within the dose range of 150–600 mg/day.
Diabetes Care, 2005
+2.1 m/s
Nerve Conduction Velocity
Improvement vs. Placebo
Improvement vs. Placebo
−40%
Pain Score Reduction
(VAS Scale)
(VAS Scale)
✓ Safe
No Liver/Kidney
Toxicity Reported
Toxicity Reported
5
Stability and Compatibility of Preparations
Benfotiamine is significantly more stable than ordinary B1 in an acidic environment (pH 2.0–4.0): degradation rate <5% vs. >30% for standard thiamine.
It is compatible with a variety of multivitamins or drug preparations. Its lipid-soluble properties support the development of delivery systems such as nanoemulsions and liposomes, further improving the efficiency of targeted delivery.
?
Frequently Asked Questions
Q1
What is benfotiamine and how does it differ from regular vitamin B1?
Benfotiamine is a synthetic, lipid-soluble derivative of thiamine (vitamin B1). Unlike ordinary water-soluble B1, which relies on saturable intestinal transporters and has an absorption rate of less than 5%, benfotiamine bypasses these limitations through passive diffusion — achieving absorption efficiency above 80% and bioavailability 3–5 times higher than standard thiamine.
Q2
Why is benfotiamine more effective for diabetic neuropathy?
Benfotiamine targets multiple pathways involved in hyperglycemic damage: it inhibits AGE formation, suppresses NF-κB and NLRP3 inflammasome activity, and restores mitochondrial function via the PDH complex. Its superior tissue penetration — especially into nerve tissue — makes it far more effective than ordinary B1 for addressing the underlying causes of diabetic neuropathy.
Q3
What is the recommended dosage of benfotiamine in clinical settings?
Clinical studies have used benfotiamine at doses ranging from 150 to 600 mg per day. Within this range, it has been shown to stably increase thiamine pyrophosphate (TPP) levels in tissues, improve nerve conduction velocity, and significantly reduce pain scores — without reports of liver or kidney toxicity.
Q4
Can benfotiamine cross the blood-brain barrier?
Yes. Due to its lipid-soluble nature, benfotiamine penetrates the blood-brain barrier and nerve sheaths at a rate 8–10 times greater than ordinary vitamin B1. This makes it particularly effective for conditions involving the central and peripheral nervous systems.
Q5
Is benfotiamine stable in acidic environments like the stomach?
Benfotiamine demonstrates significantly greater stability in acidic conditions (pH 2.0–4.0) compared to regular B1 — with a degradation rate of less than 5% versus more than 30% for standard thiamine. This ensures more consistent delivery and absorption through the gastrointestinal tract.
Q6
What advanced drug delivery forms are available for benfotiamine?
Thanks to its lipid-soluble properties, benfotiamine is compatible with advanced pharmaceutical delivery systems including nanoemulsions and liposomal formulations. These technologies further enhance targeted delivery efficiency and may improve therapeutic outcomes compared to standard oral capsule or tablet forms.